Penny L. Moore

This study finds low neutralizing antibody prevalence to GRAd32 in southern African populations, suggesting its potential as an HIV vaccine vector despite prior Ad26 vaccination.

This paper develops updated HIV-1 pseudovirus panels to better detect and assess B cell lineages with potential to produce broadly neutralizing antibodies against contemporary HIV-1 variants.

The paper uses cfDNA/cfRNA sequencing to identify molecular correlates of bNAb development in HIV patients, finding an MHC class I activation signature and microbial changes associated with bNAb production.

The paper analyzes HIV breakthrough virus populations in antibody-mediated prevention trials, finding high rates of multilineage infections and recombination under VRC01 treatment.

The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.

This study identifies VRC01-mediated viral escape mutations in HIV-infected participants from antibody-mediated prevention trials, showing that VRC01 can select for escape variants with cross-resistance to other CD4bs bnAbs.

The paper identifies a new broadly neutralizing antibody, 04_A06, with high potency and breadth against HIV-1 strains, showing potential for prevention and therapy.

BRAVE predicts HIV-1 resistance to 33 bNAbs using a Random Forests classifier with a protein language model, outperforming existing tools in accuracy and other metrics.

This study compares neutralization profiles of contemporary HIV-1 clade C viruses from India and South Africa against broadly neutralizing antibodies, finding distinct resistance patterns and env signatures.

The paper identifies rare twin cysteine residues in HIV-1 Env V1 linked to neutralization escape and breadth development.